Immupharma Regulatory News (IMM)

2 Jul 2008 07:30



ImmuPharma PLC

Long term toxicology studies confirmed the safety of LupuzorTM

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces today LupuzorTM its treatment for Lupus, a chronic, life-threatening autoimmune disease, completed the first leg of the mandatory long term toxicology study package. International regulations require two long term toxicology studies (6 and 9 months) for drug products intended to be use chronically. ImmuPharma reports that the first study has been completed and that there was no clinical or laboratory findings suggesting any safety issues. Further, an interim analysis of the second study supported these findings. These studies were requirements from The FDA (Food and Drug Administration) in the US prior to initiating ImmuPharma's Phase III programme.

For further information please contact: 

For further company information, visit www.immupharma.com